首页> 美国卫生研究院文献>BMJ Open >Risk of a seizure recurrence after a breakthrough seizure and the implications for driving: further analysis of the standard versus new antiepileptic drugs (SANAD) randomised controlled trial
【2h】

Risk of a seizure recurrence after a breakthrough seizure and the implications for driving: further analysis of the standard versus new antiepileptic drugs (SANAD) randomised controlled trial

机译:突破性癫痫发作后癫痫发作复发的风险及其对驾驶的影响:标准与新抗癫痫药物(SANAD)随机对照试验的进一步分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectivesA breakthrough seizure is one occurring after at least 12 months seizure freedom while on treatment. The Driver and Vehicle Licensing Agency (DVLA) allows an individual to return to driving once they have been seizure free for 12 months following a breakthrough seizure. This is based on the assumption that the risk of a further seizure in the next 12 months has dropped <20%. This analysis considers whether the prescribed 1 year off driving following a breakthrough seizure is sufficient for this and stratifies risk according to clinical characteristics.
机译:目的突破性癫痫发作是指在治疗期间至少发作12个月以上而发生癫痫发作。驾驶员和车辆许可机构(DVLA)允许个人在突破性癫痫发作后12个月内无癫痫发作后恢复驾驶。这是基于以下假设:在未来12个月内进一步发作的风险下降了<20%。该分析考虑了突破性癫痫发作后开出的规定的一年开车是否足够,并根据临床特征对风险进行了分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号